The considerable heterogeneity of outcomes and measurement instruments in hand eczema trials substantially limits the evidence synthesis concerning therapeutic and preventive interventions. Therefore, the Hand Eczema Core Outcome Set (HECOS) initiative is developing a core outcome set for future trials. The first objective was to identify outcomes that were measured in previous trials, to group them in domains, and to identify their measurement instruments. We conducted a systematic review of controlled and randomized controlled hand eczema trials published since 2000. Sixty-one eligible studies were identified. Each assessed one or more of 47 outcomes in the "skin" domain. Eighteen trials (30%) additionally focused on preventive behaviour in risk occupations. Quality of life was measured in 13 studies (21%). Thirty-two distinct named instruments were applied, but 223 measurements (62%) were conducted with unnamed instruments. Only 32 studies (52%) defined a primary outcome. Twenty-nine trials (48%) provided some information on adverse events, but none gave any references concerning relevant methods. Our review confirms the need to harmonize outcome measurements in hand eczema trials. The findings form the basis for a consensus process to generate a core outcome set to improve the explanatory power and comparability of future hand eczema studies.
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| INTRODUCTION
Hand eczema is a complex, multifactorial and impairing skin disease.
With a 1-year prevalence of nearly 10%, it is common in the general population. 1 Moreover, occupational hand eczema is one of the most common occupational diseases, and constitutes 40% of all occupational diseases in industrialized nations causing a substantial psychological and economic burden for affected individuals and society. [2] [3] [4] [5] Considerable research efforts are therefore being made in order to develop and evaluate interventions aimed at preventing the development, recurrence or worsening of hand eczema, or to ease its burden. However, trials studying these interventions use a variety of outcomes to determine their success. The problems arising from such heterogeneity have been explained in detail by the Core Outcome Measures in Effectiveness Trials (COMET) initiative. 6 In short, heterogeneity considerably limits the comparability and overall confidence in the study results, and thereby the strength of recommendations for clinical practice. 7 To help overcome these problems, the Hand Eczema Core Outcome Set (HECOS) initiative was formed. This international working group of dermatologists and researchers experienced in hand eczema trials aims to develop a core outcome set for standardized evaluation of therapeutic and preventive interventions in future hand eczema trials and reviews. This core outcome set will define the minimum that should be measured and reported in interventional trials of hand eczema. 8 Apart from enhancing the methodological quality, comparability and usefulness of hand eczema trials for clinical decision-making, the core outcome set will also considerably reduce the effort involved in planning, conducting and reporting individual hand eczema studies, as well as reviews and meta-analyses. The methodology of the HECOS will follow the guidance provided by the Cochrane Skin
Group Core Outcomes Set Initiative (CS-COUSIN). 9, 10 As an early step in the core outcome set development, we systematically reviewed controlled or randomized controlled hand eczema trials published since 2000, covering all types of participants, interventions, and comparisons. We aimed to identify the outcomes that they measured (eg, "itch"), to group relatively similar outcomes in domains (eg, "skin"), and to specify the instruments that were applied to measure them (eg, "visual analogue scale"). This overview will facilitate the HECOS consensus process by providing an overview of relevant outcomes and instruments to be considered for the core outcome set.
| METHODS
The review was conducted according to an unpublished protocol.
| Explanation of terms
No distinction was made between efficacy and effectiveness outcomes.
We distinguished between outcomes, outcome domains, outcome mea- was not possible, full texts were obtained and evaluated. All differences were resolved by discussion, involving a third investigator when needed.
| Data extraction
Full texts were obtained for all eligible studies. A data extraction template (including guidance for its use) was developed and pretested. All relevant information was extracted independently by two researchers for each trial: study details, data on efficacy/effectiveness outcomes, data on safety outcomes, and baseline characteristics. Discrepancies were resolved by discussion, and, in the case of conflict, a third investigator was involved.
Reported outcomes that were not specified in the article's methods section were also included. All efficacy and safety outcomes were extracted, even when they were considered to be unrelated to hand eczema. Control variables/factors were not extracted. The identified efficacy outcomes were mapped according to the taxonomy developed by the COMET initiative. 13 In accordance with this taxonomy, both clinical signs and symptoms were classified within the "physiological or clinical" core area. Composite outcomes addressing several domains were classified within each of the covered domains.
3 | RESULTS
| Included studies
After removing duplicates, we identified and screened 938 potentially eligible records ( Figure 1 ). Twenty-four of these articles were written in languages other than English or German, and were therefore excluded. Two of them (one Turkish and one Polish) were potentially eligible (apart from the language criterion), as judged from their abstracts. Most studies were conducted in Europe (Table 1) . Finally, interventions. One trial investigated the effects of a nickel-reduced diet in nickel-sensitive hand eczema patients.
The following study characteristics apply to the studies for which they were reported. A total of 12 620 participants were recruited, ranging from 8 to 1649 per study. The average participant age per study ranged from 17 to 55 years. More women than men were included (62% females, unweighted mean).
| Efficacy/effectiveness outcomes and outcome measurement instruments
Thirty-two studies defined a primary outcome (25% of controlled clinical trials and 62% of randomized controlled trials); 26 of them defined one primary outcome, and the remaining trials defined up to five primary outcomes. More recent trials were more likely to define a primary 
| "Skin" domain
Most outcomes, by far, were measured in the "skin" domain (all 61 trials; Figure 2 ). In accordance with the taxonomy, this domain covers physiological/clinical skin outcomes, including physiological function, signs, and symptoms. Forty-seven skin outcomes were assessed in hand eczema trials ( Table 2 ).
The most often applied outcome measurement instrument in the skin domain was an item of the Dermatology Quality of Life Index (DLQI; "Over the last week, how itchy, sore, painful or stinging has your skin been?"; 10 trials), but this was not reported as a separate outcome. The Hand Eczema Severity Index (HECSI) was applied in six trials and Tewameter measurements were applied in eight trials. Other outcomes were assessed in <10% of the trials (Supporting Information   Table S3 ).
| "Delivery of care" domain
The second largest domain was "delivery of care," in particular the subdomain "adherence/compliance." This subdomain was important in prevention trials in occupations with a particular risk of developing hand eczema. There, it referred to skin protective behaviour of the employees (18 trials) and preventive measures provided by the employer (5 trials). A list of all 72 non-skin outcomes is provided in Supporting Information Table S4 .
| "Functioning" and other domains
The domains "physical functioning" (13 trials), "social functioning" 
| Properties of the outcome measurements
Of the total of 360 measurements, a vast majority of 195 were patient-reported (33% of the measurements conducted in therapeutic trials, and 69% of the measurements in prevention trials). Sixtytwo measurements were performed by physicians, eight were performed by other study personnel, and 19 were patient-reported, as Outcome domains of efficacy outcomes categorized according to Dodd et al. 13 . Empty domains are not displayed 204 RÖNSCH ET AL.
| Safety outcomes
Thirteen trials reported the methods used to detect adverse events.
Six of these methods were unspecified (eg, stating that adverse events were recorded). Another 16 trials reported adverse events without mentioning the methods used to detect them. None of the studies gave any references concerning methods of registering adverse events.
| DISCUSSION
To our knowledge, this is the first systematic review to summarize the use of outcomes and outcome measurement instruments in hand eczema trials. It is part of the HECOS initiative, and will form the basis for developing a core outcome set for future hand eczema trials.
Sixty-one eligible studies were identified.
| Outcomes in the "skin" and other domains
Not surprisingly, the majority of all measurements were conducted within the "skin" domain. However, 47 distinct skin outcomes were measured, encompassing various symptoms such as itching or pain, clinical signs such as vesicles or scaling, overall ratings of hand eczema severity or extent, and parameters with unclear relevance for hand eczema, such as skin surface pH or skin contrast. The complete list of these outcomes will be used in a Delphi survey to determine which are considered to be crucial by patients, clinicians, investigators, and other stakeholders. Other domains were investigated mainly to evaluate the participants' HR-QoL and their ability to work, and outcomes related to the prevention of occupational hand eczema. The outcomes will be considered in the Delphi survey.
| Differences between therapeutic and prevention trials
In the "skin" domain, half of the outcomes were measured in both therapeutic and prevention trials. For the remaining outcomes (with the exception of "ever had hand eczema"), no reason why these outcomes should not be eligible for both types of study was apparent. Across all domains, prevention trials conducted more than twice as many measurements per trial than therapeutic trials, and the proportion of patient-reported outcomes was twice as high. Prevention trials also applied more unnamed instruments.
Most of the outcomes that were exclusively used in prevention trials belonged to the domain "delivery of care," in particular the uptake of protective behaviour and the status of skin protection at the workplace. These intermediate outcomes do not directly benefit the patient. Instead, it is assumed that they are associated with physiological outcomes. As 38% of the trials addressed prevention strategies, an extended core outcome set will probably be necessary for prevention trials, which will be considered in the consensus process to identify core outcomes. This concerns, in particular, the assessment of skin impairment, for which a large number of instruments were applied. Across other domains as well, unnamed instruments, predominantly questionnaires, were applied more than twice as often as named instruments.
| Safety outcomes
Although an in-depth analysis of the applied safety outcomes will be covered in another publication, it is already apparent that none of the included studies provided any references concerning safety outcomes.
The Patient-Reported Outcomes Safety Event Reporting (PROSPER)
Consortium Guidance provides insights on how to gather such outcomes. 15 This process involves validating the instruments that measure safety outcomes, which so far has not been reported for any of the included hand eczema trials. Complementary, more specific guidance on clinician-reported safety outcomes is needed for hand eczema studies. The US National Institutes of Health Ongoing Trials
Register offers detailed advice on how to report safety outcomes. 16 The HECOS will provide guidance on how to collect such data with validated instruments in hand eczema trials.
| Outcome taxonomy
A recent review by Dodd et al 13 showed that, despite the availability of a variety of outcome taxonomies, none of them was sufficient for categorizing the outcomes of all clinical trials. They developed a new taxonomy, which proved to be very suitable for categorizing the outcomes identified in our review. It is structured as five core areas and domains within these areas, and also provides comprehensive guidance on how to map outcomes accordingly. Most outcomes that were identified by our review could be fitted into exactly one of the domains. Only HR-QoL outcomes were difficult to map, because the taxonomy requires the categorization of composite outcomes within each domain covered by their components, and some individual questionnaire items did not fit the domains well. In the DLQI, 17 for example, the first question ("Over the last week, how itchy, sore, painful or stinging has your skin been?") was considered as an item that addresses skin symptoms, and was therefore classified in the "skin" domain. If the item had a slightly different wording (such as "How much did you suffer from itchy, sore, painful or stinging skin?"), it would cover the "emotional functioning/wellbeing" category instead. For another DLQI question ("Over the last week, how much has your skin influenced the clothes you wear?"), no category was completely appropriate-the question may refer to social or emotional functioning, or neither. Although we agree with Dodd et al that it is important to identify the content of score components for some purposes, this may not be necessary for many other objectives. Composite scores are designed to measure constructs (such as HR-QoL) as a whole, and we therefore consider that it would be appropriate to categorize them at the construct level. Also, the categorization process would be simpler and would result in less variability between raters. In this review, however, composite outcomes were categorized at the component level as proposed by the taxonomy developers. This approach was accompanied by the uncertainties described above for HR-QoL scores, but other composite outcomes were not affected, because all of their components fell into the "skin" domain.
| Strengths and limitations
Our review has some limitations. First, it was restricted to articles published since 2000 in English or German. Thus, outcomes and measurement instruments that were exclusively published in older articles or other languages were not considered. However, only two additional articles would have been eligible without the language restriction.
Second, we were unable to assess how many of the unnamed instruments were actually identical. The photographic guide developed by Coenraads et al, 18 for instance, was used in several studies, but, from the data gathered, it was impossible to determine the exact number.
Other outcomes, such as various three-point scales of skin impairment, appeared similar, but also lacked a name to clarify whether or not they were identical. A strength of this review was that the databases were searched intensely for all eligible trials and all data were extracted in duplicate with a pretested template, so that we are confident that all contemporary hand eczema outcomes and outcome measurement instruments were covered in this review insofar they were applied in controlled trials.
| CONCLUSION
This review provides an overview of efficacy/effectiveness outcomes that have been applied in interventional hand eczema trials since 2000. Our findings confirm the need for harmonization of outcome measurement instruments and for promotion of the use of validated instruments.
The results of the review form the basis for a consensus process to generate a core outcome set. In the course of the project, the core outcome set is going to be completed by determining appropriate, validated measurement instruments for each relevant domain. This systematic review ensures that all previously applied outcomes will be considered in this process. As a result of this harmonization, the explanatory power and comparability of future hand eczema trials will be improved considerably.
Researchers who are planning new hand eczema trials are invited to visit the HECOS website for updates. Scientists, clinicians and patients who wish to participate in the HECOS are encouraged to contact us.
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